Zarrabian Saiid 4
4 · Kintara Therapeutics, Inc. · Filed Sep 17, 2020
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Award
Options (Right to Buy)
2020-09-15+2,715,004→ 2,715,004 totalExercise: $1.70Exp: 2030-09-15→ Common Stock (2,715,004 underlying)
Footnotes (1)
- [F1]The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.